Oral anti coagulants ppt
-
Upload
renjusravi -
Category
Health & Medicine
-
view
423 -
download
0
Transcript of Oral anti coagulants ppt
![Page 1: Oral anti coagulants ppt](https://reader036.fdocuments.net/reader036/viewer/2022062523/5873fd641a28abb1528b76cb/html5/thumbnails/1.jpg)
ORAL ANTICOAGULANTS
Dr. RENJU.S.RAVI MD
![Page 2: Oral anti coagulants ppt](https://reader036.fdocuments.net/reader036/viewer/2022062523/5873fd641a28abb1528b76cb/html5/thumbnails/2.jpg)
HEMOSTASIS
![Page 3: Oral anti coagulants ppt](https://reader036.fdocuments.net/reader036/viewer/2022062523/5873fd641a28abb1528b76cb/html5/thumbnails/3.jpg)
PLATELET PLUG FORMATION
![Page 4: Oral anti coagulants ppt](https://reader036.fdocuments.net/reader036/viewer/2022062523/5873fd641a28abb1528b76cb/html5/thumbnails/4.jpg)
COAGULATION CASCADE
![Page 5: Oral anti coagulants ppt](https://reader036.fdocuments.net/reader036/viewer/2022062523/5873fd641a28abb1528b76cb/html5/thumbnails/5.jpg)
ANTICOAGULANTSI) USED INVIVO
PARENTERAL Unfractionated heparin (UFH) Low molecular weight heparin(LMWH) –
Enoxaparin, Dalteparin, Ardeparin, Nadroparin, Pamparin, Reviparin, Tinzaparin
Heparinoids- heparan sulfate, danaproid, ancrod Fondaparinux Direct thrombin inhibitor – lepirudin, argatroban
bivalirudin Drotrecogin Alfa – human recombinant activated
protein C
![Page 6: Oral anti coagulants ppt](https://reader036.fdocuments.net/reader036/viewer/2022062523/5873fd641a28abb1528b76cb/html5/thumbnails/6.jpg)
ORAL Coumarin derivatives-
bishydroxycoumarin, Warfarin, acenocoumarol, ethylbiscoumacetate
Indanedione derivative- Phenindione
II)USED INVITRO Heparin- 150 U for 100 ml blood Calcium complexing agents – sodium
citrate, sodium oxalate, sodium edetate
![Page 7: Oral anti coagulants ppt](https://reader036.fdocuments.net/reader036/viewer/2022062523/5873fd641a28abb1528b76cb/html5/thumbnails/7.jpg)
WARFARIN Discovered after report of
hemorrhagic disorder in cattle ingested spoiled sweet clover (d/t dicoumarol) – Campbell & Link
Racemic mixture of R & S isomersf. II, VII, IX,X Carboxylated f.II,VII,IX,X
![Page 8: Oral anti coagulants ppt](https://reader036.fdocuments.net/reader036/viewer/2022062523/5873fd641a28abb1528b76cb/html5/thumbnails/8.jpg)
WARFARIN Rapid, complete absorption from GIT
Plasma half life 36-42 hrs
>97% PPB
S isomer oxidative metabolised by CYP2C9
2 variants CYP2C9*2,CYP2C9*3 – reduced activity
![Page 9: Oral anti coagulants ppt](https://reader036.fdocuments.net/reader036/viewer/2022062523/5873fd641a28abb1528b76cb/html5/thumbnails/9.jpg)
WARFARIN cont… Crosses placenta
Resistance with advanced GI Cancer & hereditary
Started at 5-10 mg dose along with parenteral anticoagulant for 5 days
Monitored by PT with target INR 2-3; 2.5 – 3.5 in pts with mechanical prosthetic valves
![Page 10: Oral anti coagulants ppt](https://reader036.fdocuments.net/reader036/viewer/2022062523/5873fd641a28abb1528b76cb/html5/thumbnails/10.jpg)
DRUG INTERACTIONS
![Page 11: Oral anti coagulants ppt](https://reader036.fdocuments.net/reader036/viewer/2022062523/5873fd641a28abb1528b76cb/html5/thumbnails/11.jpg)
Long acting sulfonamides, Phenytoin, Indomethacin, Probenecid, phenylbutazone displace warfarin from plasma protein binding
![Page 12: Oral anti coagulants ppt](https://reader036.fdocuments.net/reader036/viewer/2022062523/5873fd641a28abb1528b76cb/html5/thumbnails/12.jpg)
SIDE EFFECTS BLEEDING withhold drug - INR 3.5-4.5 asymptomatic S/L vit K - INR > 4.5 1 mg vit K - INR 4.9 – 9 2 -3 mg vit K - INR >9 10 mg slow IV along with FFP if
excessively high SKIN NECROSIS – in pts with cong or acq
def of protein C/S TERATOGENIC EFFECTS – nasal
hypoplasia, stippled epiphysis
![Page 13: Oral anti coagulants ppt](https://reader036.fdocuments.net/reader036/viewer/2022062523/5873fd641a28abb1528b76cb/html5/thumbnails/13.jpg)
OTHER COUMARIN DERIVATIVES Bishydroxy coumarin (Dicoumarol) Slowly absorbed, poor GI tolerance Acenocoumarol half life 24 hrs, acts rapidly S/E – spontaneous haemorrhage,
stomatitis, dermatitis, alopecia Ethyl biscoumacetate (Tromexane) Rapid & brief action, difficult to
maintain S/E - spontaneous haemorrhage,
alopecia
![Page 14: Oral anti coagulants ppt](https://reader036.fdocuments.net/reader036/viewer/2022062523/5873fd641a28abb1528b76cb/html5/thumbnails/14.jpg)
ORAL DTI Advantages incl predictable PK, so fixed
dosing can be given and routine monitoring unnecessary
Do not interact with P450 interacting drugs Rapid onset & offset of action XIMELAGATRAN – first oral DTI approved
but withdrawn d/t hepatotoxicity DABIGATRAN- recently approved in Europe
for Px of VTE in pts undergone hip, knee surgery
Equivalent efficacy & safety to LMWH No routine monitoring required
![Page 15: Oral anti coagulants ppt](https://reader036.fdocuments.net/reader036/viewer/2022062523/5873fd641a28abb1528b76cb/html5/thumbnails/15.jpg)
ORAL FACTOR Xa INHIBITORRIVAROXIBAN
First oral factor Xa inhibitor to reach phase III trial
Safety & efficacy atleast equivalent or better to LMWH for preventing DVT
NO routine monitoring necessary
Also in trial for Rχ of Venous thromboembolism & prevention of stroke in AF
![Page 16: Oral anti coagulants ppt](https://reader036.fdocuments.net/reader036/viewer/2022062523/5873fd641a28abb1528b76cb/html5/thumbnails/16.jpg)